PA-MONROL
24.11.2021 08:02:04 CET | Business Wire | Press release
Eczacıbaşı-Monrol Nuclear Products Co. (Monrol) today announced their agreement with Molecular Targeting Technologies, Inc. (MTTI), a clinical stage biotech company focused on developing innovative therapies for rare cancers, for the supply of the medical radioisotope no-carrier-added 177 Lu (n.c.a. 177 Lu).
Eczacıbaşı-Monrol entered the theranostic market in 2019 as one of the few producers of Lutetium-177 worldwide and since then has provided an uninterrupted supply of this critical product to patients in many countries. In line with its mission to improve the quality of life of cancer patients globally, the company is establishing strategic partnerships with international pharmaceutical companies and constructing a new production facility compliant with FDA 21 CFR Part 211 quality standards that will have an annual capacity of 60 thousand doses. Thanks to its location close to Istanbul's transportation hub, the new facility will benefit from a worldwide logistics network and agreements with cargo services to 320 destinations worldwide.
Aydin Küçük, General Manager of Eczacıbaşı-Monrol, noted that n.c.a.177 Lu contributes to the company's mission of adding value to human life with leading and innovative approaches in the diagnosis and treatment of critical diseases and added, "To support our growth in this field, we're establishing a new GMP certified facility exclusively for theranostic R&D and production with a new technology that will enable us to maximize our supply of high-quality Lutetium. Sustainability and innovation are two of our core values, and we strive for continuous improvement in our operations and products while trying to serve patients all around the world."
Molecular Targeting Technologies, Inc. (MTTI) CEO, Chris Pak said, " We’ve identified a timely and sustainable supply of a key therapeutic ingredient needed for the development and launch of our lead asset 177 Lu-EBTATE and other EB platform technologies. We are excited to start
this collaboration and build what promises to be a great relationship with a reliable and trusted radioisotope supply partner like Eczacıbaşı-Monrol for the supply of n.c.a.177 Lu.”
About Molecular Targeting Technologies, Inc. (MTTI)
Molecular Targeting Technologies, Inc. is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com
; www.evathera.com
About Eczacıbaşı-Monrol
Eczacıbaşı-Monrol Nuclear Products Co. is an innovative, international supplier of radiopharmaceuticals for diagnosis and treatment in nuclear medicine. Eczacıbaşı-Monrol is headquartered in Istanbul and delivers customer-oriented service globally.
Monrol exports high quality and a wide spectrum of nuclear medicine products to more than 50 countries around the globe and has manufacturing sites and operational projects in different regions. For more information visit www.monrol.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211123006032/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CFO Worx Named No. 448 on the 2026 Inc. 5000 List, the Most Prestigious Ranking of America’s Fastest-Growing Private Companies13.8.2026 22:21:00 CEST | Press release
Company Recognized for 776% Three-Year Revenue Growth, Earning a Place Among the Nation’s Most Successful Independent Businesses CFO Worx today announced it has been ranked No. 448 on the 2026 Inc. 5000 list, the annual list of the fastest-growing private companies in America. The list is the most prestigious ranking of the nation’s most successful independent and entrepreneurial businesses, recognizing companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Past honorees include companies such as Microsoft, Meta, Chobani, Oracle, and Patagonia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813927944/en/ Brian Alvarez, CEO of CFO Worx "Earning a place on the list comes down to the trust our clients place in us and is a testament to the caliber of the team behind every engagement," said Brian Alvarez, CEO of CFO Worx. This year’s Inc. 5000 recognizes a
Andersen Global udvider sine juridiske kompetencer gennem samarbejde med Beech Incorporated13.8.2026 18:01:00 CEST | Pressemeddelelse
Andersen Global indgår en samarbejdsaftale med det sydafrikanske advokatfirma Beech Incorporated og udvider dermed sine juridiske kompetencer i regionen. Beech Incorporated leverer juridisk og regulatorisk rådgivning til mine-, vedvarende energi-, infrastruktur-, olie- og gassektorerne med speciale inden for fusioner og opkøb, kommercielle forhold, projektfinansiering, sundhed, sikkerhed og miljø, ansættelsesret samt compliance. Firmaets tværfaglige team rådgiver klienter gennem hele projektets livscyklus – fra udvikling og finansiering til drift og interessenthåndtering – og er anerkendt som et førende advokatfirma af blandt andre publikationer somChambers and Partners og The Legal 500 . "Vores tilgang bygger på en praktisk forståelse af de brancher, vi arbejder inden for, og på at levere konkret og handlingsorienteret rådgivning til klienter, der opererer i komplekse regulatoriske miljøer," siger Warren Beech, der er CEO for Beech Incorporated. "Gennem samarbejdet med Andersen Global
BTG Pactual TIG and Conservation International Reach 20,000 Hectares of Cerrado UnderRestoration, Accelerating Latin American Reforestation Strategy, Increasing Biodiversity andSocial Impacts13.8.2026 17:47:00 CEST | Press release
BTG Pactual Timberland Investment Group (BTG Pactual TIG) and Conservation International today announced that native ecosystem restoration is now underway across more than 20,000 hectares of Brazil's Cerrado biome, marking a significant acceleration of the firms' Latin American reforestation strategy. According to data recorded by the Brazilian Restoration and Reforestation Observatory, an independent platform that tracks and maps native vegetation recovery, this further cements the strategy’s position as the largest ever restoration effort in the region. Conservation International serves as Impact Adviser for social and environmental outcomes. The strategy focuses on conserving, restoring and reforesting degraded landscapes across Latin America, including Brazil's Cerrado, one of the world’s most biodiverse and fastest disappearing seasonally dry ecosystems. More than half of the Cerrado has already been cleared for cattle ranching and farming. The strategy targets degraded cattle pas
Milliman names Jim Fulton next CEO13.8.2026 17:40:00 CEST | Press release
Fulton to assume CEO role in October after 11 years as CFO Milliman, Inc., a leading global actuarial and consulting firm, today announced that Jim Fulton has been named Milliman’s next Chief Executive Officer. Fulton has served as Milliman’s Chief Financial Officer since 2015 and has been a leader driving the firm’s organic growth and M&A strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260811027168/en/ Milliman, Inc., a leading global actuarial and consulting firm, today announced that Jim Fulton has been named Milliman’s next Chief Executive Officer. Fulton has served as Milliman’s Chief Financial Officer since 2015 and has been a leader driving the firm’s organic growth and M&A strategy. Fulton’s appointment reflects Milliman’s evolution from an actuarial firm to a multidisciplinary consultancy, risk management, and technology solution provider. His expertise includes stints with Big 4 accounting and private equi
Clinilabs Announces Leadership Expansion and Welcomes Laura Shannon as Chief Executive Officer and Promotion of Founder Gary Zammit, Ph.D., to Executive Chairperson13.8.2026 16:05:00 CEST | Press release
Clinilabs, a leading specialty contract research organization (CRO) focused on central nervous system (CNS) drug and device development, today announced leadership expansion. Laura Shannon joins the organization as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson. This expansion of the senior leadership team is a recognition of a growing organization with global capabilities and continuing commitment to advancing treatments for patients with psychiatric and neurological disorders. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260813362140/en/ Laura Shannon joins Clinilabs as Chief Executive Officer as Gary Zammit, Ph.D., the Company’s founder, assumes the role of Executive Chairperson Ms. Shannon is a dynamic leader with more than 30 years of biopharma industry experience, known for her ability to build high-performing teams, forge strategic alliances, and drive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom